Naldebain (dinalbuphine) - Lumosa Therap
cebranopadol (TRN-228) - Tris Pharma
PL265 - Pharmaleads, IACTA Pharma
STR-324 - ArchiMed
morphine sulphate - Generic mfg.
Nucynta (tapentadol) - Collegium Pharma, Grunenthal
Olinvyk (oliceridine) - Trevena
PL37 - Debiopharm
Cyt-1010 - Cytogel
Novel Opioids in the Setting of Acute Postoperative Pain: A Narrative Review. (PubMed, Pharmaceuticals (Basel)) - Jan 23, 2024 - "Although traditional opioids such as morphine and oxycodone are commonly used in the management of acute postoperative pain, novel opioids may play a role as alternatives that provide potent pain relief while minimizing adverse effects...The more established include oliceridine (biased ligand activity to activate analgesia and downregulate opioid-related adverse events), tapentadol (mu-opioid agonist and norepinephrine reuptake inhibitor), and cebranopadol (mu-opioid agonist with nociceptin opioid peptide activity)-all of which have demonstrated success in the clinical setting when compared to traditional opioids. On the other hand, dinalbuphine sebacate (DNS; semi-synthetic mu partial antagonist and kappa agonist), dual enkephalinase inhibitors (STR-324, PL37, and PL265), and endomorphin-1 analog (CYT-1010) have shown good efficacy in preclinical studies with future plans for clinical trials. Rather than relying solely on mu-opioid receptor agonism to relieve pain..." 
Journal • Review • Anesthesia • CNS Disorders • Depression • Pain • Psychiatry • PENK
http://www.ncbi.nlm.nih.gov/pubmed/38256863
 
Abhishek Gupta; Ashley Wang; Jasper Murphy; Lana Shteynman; Neil Daksla; Sergio Bergese
 
Jan 23, 2024
 
Prev Next